[Abstract] Aims. We assessed the interplay between hyperkalaemia (HK) and renin–angiotensin–aldosterone system inhibitor (RAASi) use, dose and discontinuation, and their association with all‐cause or cardiovascular death in patients with chronic heart failure (HF). We hypothesized that HK‐associated increased death may be related to RAASi withdrawal. Methods and results. The ESC‐HFA‐EORP Heart Failure Long‐Term Registry was used. Among 9222 outpatients (HF with reduced ejection fraction: 60.6%, HF with mid‐range ejection fraction: 22.9%, HF with preserved ejection fraction: 16.5%) from 31 countries, 16.6% had HK (≥5.0 mmol/L) at baseline. Angiotensin‐converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) was used i...
Background-Dosing of renin-angiotensin-aldosterone system inhibitors (RAASi) may be modified to mana...
Background: Hyperkalemia is one of the most frequent side effects related to renin-angiotensin-aldos...
Renin–angiotensin–aldosterone system inhibitors (RAASi) are known to improve outcomes in patients wh...
Aims: We assessed the interplay between hyperkalaemia (HK) and renin–angiotensin–aldosterone system ...
AIMS We assessed the interplay between hyperkalaemia (HK) and renin-angiotensin-aldosterone syste...
OBJECTIVES: This study investigated associations between incident hyperkalemia during acute heart...
OBJECTIVES This study investigated associations between incident hyperkalemia during acute heart fai...
Renin–angiotensin–aldosterone system inhibitors (RAASi) are known to improve outcomes in patients wh...
Renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in patients wh...
Background: Hyperkalaemia is a common co-morbidity in patients with heart failure with reduced ejec...
Introduction and Objectives: Renin-angiotensin-aldosterone system inhibitors (RAASi) are the corners...
Introduction and Objectives: Renin-angiotensin-aldosterone system inhibitors (RAASi) are the corners...
Renin–angiotensin–aldosterone system inhibitors (RAASi) reduce morbidity and mortality in heart fail...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/143644/1/ejhf1175.pdfhttps://deepblue....
Background-Dosing of renin-angiotensin-aldosterone system inhibitors (RAASi) may be modified to mana...
Background: Hyperkalemia is one of the most frequent side effects related to renin-angiotensin-aldos...
Renin–angiotensin–aldosterone system inhibitors (RAASi) are known to improve outcomes in patients wh...
Aims: We assessed the interplay between hyperkalaemia (HK) and renin–angiotensin–aldosterone system ...
AIMS We assessed the interplay between hyperkalaemia (HK) and renin-angiotensin-aldosterone syste...
OBJECTIVES: This study investigated associations between incident hyperkalemia during acute heart...
OBJECTIVES This study investigated associations between incident hyperkalemia during acute heart fai...
Renin–angiotensin–aldosterone system inhibitors (RAASi) are known to improve outcomes in patients wh...
Renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in patients wh...
Background: Hyperkalaemia is a common co-morbidity in patients with heart failure with reduced ejec...
Introduction and Objectives: Renin-angiotensin-aldosterone system inhibitors (RAASi) are the corners...
Introduction and Objectives: Renin-angiotensin-aldosterone system inhibitors (RAASi) are the corners...
Renin–angiotensin–aldosterone system inhibitors (RAASi) reduce morbidity and mortality in heart fail...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/143644/1/ejhf1175.pdfhttps://deepblue....
Background-Dosing of renin-angiotensin-aldosterone system inhibitors (RAASi) may be modified to mana...
Background: Hyperkalemia is one of the most frequent side effects related to renin-angiotensin-aldos...
Renin–angiotensin–aldosterone system inhibitors (RAASi) are known to improve outcomes in patients wh...